Initial Testing of the MDM2 Inhibitor RG7112 by the Pediatric Preclinical Testing Program

BACKGROUND: RG7112 is a selective inhibitor of p53-MDM2 binding that frees p53 from negative control, activating the p53 pathway in cancer cells leading to cell cycle arrest and apoptosis. RG7112 was selected for evaluation by the Pediatric Preclinical Testing Program (PPTP) due to the relatively lo...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Carol, Hernan, Reynolds, C. Patrick, Kang, Min H., Keir, Stephen T., Maris, John M., Gorlick, Richard, Kolb, E. Anders, Billups, Catherine A., Geier, Brian, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A., Lock, Richard B.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3495996/
https://ncbi.nlm.nih.gov/pubmed/22753001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.24235
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky